Pharmafile Logo
Pharmafocus logo
Advanced Search

Market Access

Showing 4 posts of 19 posts found.

bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025 Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
News
europe-1395916_640

EU approval granted for rare kidney disease treatment

April 29, 2025 Market Access, Research and Development, Sales and Marketing CSL Vifor, EU, Nephrology, Travere Therapeutics, kidney disease, nephrology

The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ therapy for primary IgA nephropathy …
News

Nordic Pharma’s Lacrifill canalicular gel gains CE mark approval and set for European launch

April 14, 2025 Market Access, Research and Development, Sales and Marketing Nordic Pharma, Opthalmology, dry eye disease

International pharma company Nordic Pharma has announced that its Lacrifill treatment for dry eye disease has received European Conformity (CE) …
News
cdc-d5nff1slguy-unsplash

FDA approves Pfizer’s pneumococcal conjugate vaccine for infants and children

April 28, 2023 Market Access, Research and Development, Sales and Marketing Ear Nose & throat, FDA, Immunology, Pfizer, Vaccine, pneumococcal vaccine

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026